WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H319612
CAS#: 402567-16-2
Description: Firategrast, also known as SB-683699 or T-0047, is an orally bioavailable alpha4 beta1/alpha4 beta7 integrin antagonist designed to reduce trafficking of lymphocytes into the central nervous system (CNS). This could decrease multiple sclerosis (MS) activity, but may compromise CNS immune surveillance. The integrins are a sort of transmembrane receptors that modulate the signal transduction from ECM to the cell. They are associated with a lot of diseases such as cancer, inflammation and thrombotic diseases.
Hodoodo Cat#: H319612
Name: Firategrast
CAS#: 402567-16-2
Chemical Formula: C27H27F2NO6
Exact Mass: 499.18
Molecular Weight: 499.511
Elemental Analysis: C, 64.92; H, 5.45; F, 7.61; N, 2.80; O, 19.22
Synonym: SB-683699; SB 683699; SB683699; T-0047; T 0047; T0047; Firategrast
IUPAC/Chemical Name: (2S)-2-[(2,6-difluorobenzoyl)amino]-3-[4-[4-(ethoxymethyl)-2,6-dimethoxyphenyl]phenyl]propanoic acid
InChi Key: YLFZHHDVRSYTKT-NRFANRHFSA-N
InChi Code: InChI=1S/C27H27F2NO6/c1-4-36-15-17-13-22(34-2)24(23(14-17)35-3)18-10-8-16(9-11-18)12-21(27(32)33)30-26(31)25-19(28)6-5-7-20(25)29/h5-11,13-14,21H,4,12,15H2,1-3H3,(H,30,31)(H,32,33)/t21-/m0/s1
SMILES Code: O=C(O)[C@@H](NC(C1=C(F)C=CC=C1F)=O)CC2=CC=C(C3=C(OC)C=C(COCC)C=C3OC)C=C2
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 499.51 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Halland N, Blum H, Buning C, Kohlmann M, Lindenschmidt A. Small Macrocycles As
Highly Active Integrin α2β1 Antagonists. ACS Med Chem Lett. 2014 Jan
10;5(2):193-8. doi: 10.1021/ml4004556. eCollection 2014 Feb 13. PubMed PMID:
24900800; PubMed Central PMCID: PMC4027761.
2: Lu E, Wang BW, Alwan S, Synnes A, Dahlgren L, Sadovnick AD, Tremlett H. A
review of safety-related pregnancy data surrounding the oral disease-modifying
drugs for multiple sclerosis. CNS Drugs. 2014 Feb;28(2):89-94. doi:
10.1007/s40263-013-0131-5. Review. PubMed PMID: 24343726.
3: Grove RA, Shackelford S, Sopper S, Pirruccello S, Horrigan J, Havrdova E, Gold
M, Graff O. Leukocyte counts in cerebrospinal fluid and blood following
firategrast treatment in subjects with relapsing forms of multiple sclerosis. Eur
J Neurol. 2013 Jul;20(7):1032-42. doi: 10.1111/ene.12097. Epub 2013 Feb 18.
PubMed PMID: 23419064.
4: Prat A, Stüve O. Firategrast: natalizumab in a pill? Lancet Neurol. 2012
Feb;11(2):120-1. doi: 10.1016/S1474-4422(11)70306-4. Epub 2012 Jan 5. PubMed
PMID: 22226930.
5: Miller DH, Weber T, Grove R, Wardell C, Horrigan J, Graff O, Atkinson G, Dua
P, Yousry T, Macmanus D, Montalban X. Firategrast for relapsing remitting
multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled
trial. Lancet Neurol. 2012 Feb;11(2):131-9. doi: 10.1016/S1474-4422(11)70299-X.
Epub 2012 Jan 5. PubMed PMID: 22226929.